Aligos TherapeuticsALGS
13F holders, Q2 2026 (June 30)At the end of Q2 2026, 31 institutions reported holding Aligos Therapeutics Inc. (ALGS) in their 13F filings, down 3 from Q1 2026. 5 opened new positions and 8 sold out. The largest holders were Deep Track Capital, LP ($2.6M), Alyeska Investment Group, L.P. ($2.4M) and Sio Capital Management, LLC ($1.9M). 2 famous investors held it, including David E. Shaw (0.0% of D. E. Shaw & Co.'s portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Aligos Therapeutics Inc.
- CUSIP
- 01626L204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $390K |
| Exits | 8 | $4.0M |
All 13F filers, Q1 2026 → Q2 2026: 167,534 shares bought and 650,082 shares sold, net −482,548 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 31 holders
| Deep Track Capital, LP | 0.04% | No change | 444,110 | $2.6M |
| Alyeska Investment Group, L.P. | 0.01% | No change | 412,000 | $2.4M |
| Sio Capital Management, LLC | 0.32% | No change | 327,237 | $1.9M |
| Marshall Wace, LLP | 0.00% | Reduce -7.7% | 246,579 | $1.4M |
| Woodline Partners LP | 0.00% | No change | 177,362 | $1.0M |
| Vanguard Capital Management LLC | 0.00% | Reduce -1.5% | 175,543 | $1.0M |
| Baker Bros. Advisors LP | 0.00% | No change | 83,055 | $479K |
| HHLR Advisors, LTD. | 0.05% | No change | 76,247 | $440K |
| D. E. Shaw & Co. | 0.00% | Add +505.4% | 66,463 | $383K |
| UBS Group AG | 0.00% | Add +61.9% | 59,986 | $346K |
| Geode Capital Management, LLC | 0.00% | Reduce -5.6% | 47,173 | $272K |
| Jane Street Group, LLC | 0.00% | New | 32,402 | $187K |
| BlackRock, Inc. | 0.00% | Add +132.3% | 30,292 | $175K |
| Vanguard Fiduciary Trust Co. | 0.00% | Add +0.6% | 28,612 | $165K |
| Dimensional Fund Advisors LP | 0.00% | New | 21,044 | $121K |
| Verition Fund Management LLC | 0.00% | No change | 18,887 | $109K |
| Trexquant Investment LP | 0.00% | New | 12,339 | $71K |
| Renaissance Technologies | 0.00% | Reduce -89.3% | 10,800 | $62K |
| Rockefeller Capital Management L.P. | 0.00% | No change | 10,000 | $58K |
| Federation des caisses Desjardins du Quebec | 0.00% | Add +389.5% | 4,650 | $27K |
| Golden State Wealth Management, LLC | 0.00% | No change | 2,674 | $15K |
| Royal Bank of Canada | 0.00% | No change | 2,125 | $12K |
| Citigroup Inc. | 0.00% | New | 1,808 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +452.3% | 359 | $2K |
| JPMorgan Chase & Co. | 0.00% | Reduce -49.0% | 344 | $2K |
| Morgan Stanley | 0.00% | Reduce -6.4% | 204 | $1K |
| SBI Securities Co., Ltd. | 0.00% | Add +384.6% | 126 | $727 |
| Wells Fargo & Company | 0.00% | Reduce -85.7% | 100 | $577 |
| FMR LLC | 0.00% | New | 10 | $58 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 4 | $24 |
| BNP Paribas Financial Markets | 0.00% | No change | 3 | $17 |
"% of holder's portfolio" is ALGS's weight in each manager's 13F, not the share of Aligos Therapeutics Inc. the manager owns.